scholarly journals Evaluation of host quality of life and immune function in breast cancer patients treated with combination of adjuvant chemotherapy and oral administration of Lentinula edodes mycelia extract

2013 ◽  
pp. 853 ◽  
Author(s):  
Yukiko Nagashima ◽  
Maeda ◽  
Yamamoto ◽  
Yoshino ◽  
Oka
The Breast ◽  
2017 ◽  
Vol 32 ◽  
pp. S28
Author(s):  
W. Yeo ◽  
F. Mo ◽  
E. Pang ◽  
J. Suen ◽  
K. Lee ◽  
...  

2018 ◽  
Vol Volume 10 ◽  
pp. 383-389 ◽  
Author(s):  
Winnie Yeo ◽  
Frankie KF Mo ◽  
Elizabeth Pang ◽  
Joyce JS Suen ◽  
Jane Koh ◽  
...  

2021 ◽  
Author(s):  
Ying Gao ◽  
Yao Wang ◽  
Hongchu Chen ◽  
Ran Yan ◽  
Tao Liu ◽  
...  

Abstract BackgroundRadical mastectomy may lead to suppression of cellular immune function in patients with malignant tumors, and affect the quality of life (QOL) of patients. Immune suppression is a common cause of complications and adverse reactions in adjuvant therapy after radical mastectomy of breast cancer. Currently, there are few proven effective treatments for immune suppression. Therefore, it’s necessary to develop a new treatment method. Press needle is widely used in clinical practice. However, there have been relatively few studies that evaluate the effects of press needle on postoperative immune function. The aim of the present study is to assess the effects of press needle on immune function and QOL in female breast cancer patients undergoing radical mastectomy.MethodsThis study will be a single-center, randomized and single-blinded trial. 78 eligible patients will be randomized in a ratio of 1:1 to the press needle group or the sham press needle group. During the treatment phase, patients will undergo five times weekly of verum press needle or sham press needle for 2 weeks, and then they will be followed-up for 2 weeks. The primary outcome measures will be the peripheral blood levels of CD8+, CD4+, CD3+, and CD4+/CD8+ T cells. The secondary outcome measures will be the changes of patients’ QOL, evaluated by the Karnofsky Performance Scale (KPS) score and the EORTC core quality of life questionnaire (EORTC QLQ-C30). Safety and adverse events will be assessed at each visit. DiscussionThe results of this on-going study will provide clinical evidence for the effects and safety of press needle on immune function and QOL in patients after breast cancer resection compared with sham press needle.Trial registrationChinese Clinical Trial Registry, ChiCTR2000040100. Registered on 21 November 2020.


2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Wilfried Tröger ◽  
Zdravko Ždrale ◽  
Nevena Tišma ◽  
Miodrag Matijašević

Background. Breast cancer patients receiving adjuvant chemotherapy often experience a loss of quality of life. Moreover chemotherapy may induce neutropenia. Patients report a better quality of life when additionally treated with mistletoe products during chemotherapy.Methods. In this prospective randomized open-label pilot study 95 patients were randomized into three groups. All patients were treated with an adjuvant chemotherapy. The primary objective of the study was quality of life, the secondary objective was neutropenia. Here we report the comparison of HxA (n= 34) versus untreated control (n= 31).Results. In the explorative analysis ten of 15 scores of the EORTC QLQ-C30 showed a better quality of life in the HxA group compared to the control group (P<0.001toP=0.038in Dunnett-T3 test). The difference was clinically relevant (difference of at least 5 points, range 5.4–12.2) in eight of the ten scores. Neutropenia occurred in 7/34 HxA patients and in 8/31 control patients (P= 0.628).Conclusions. This pilot study showed an improvement of quality of life by treating breast cancer patients with HxA additionally to CAF. Although the open design may be a limitation, the findings show the feasibility of a confirmatory study using the methods described here.


2013 ◽  
Vol 2013 (1) ◽  
pp. 4454
Author(s):  
Soo Rim Noh ◽  
Wang Lim Lee ◽  
Hee Sung Shin ◽  
Min Sun Lee ◽  
Tae Seon Baek ◽  
...  

Author(s):  
Do Quyen Phan Thi

Objective: The survey aims to explore the side effects and quality of life and its determinants among breast cancer patients who have been receiveing adjuvant chemotherapy at Oncology Center - Hue Central Hospital. Sample and Methods: This cross - sectional study deployed questionnaire - based interviews with 65 patients when they came to the hospital for adjuvant chemotherapy at Oncology Center - Hue Central Hospital from January to June 2020. Collected data was analyzed using SPSS software 21 for Windows. Results: The sample has an average age of 48,84. Among the total respondents, 50,8% had hormone receptor-positive breast cancer, 61,5% had Her2neu - positive, 7,7% was triple negative breast cancer patients. Most respondents reported having symptoms that decreased their quality of life, such as dry mouth, appetite changes, fatigue, arm pain, and limited mobility in ipsilateral arm. The majority felt insecure because of their asymmetric and less good-looking body image post mastectomy. Most were no longer interested in sexual activities. The rate of stage 3 was 35,4% but there was only 7,7% of patients who had received neo-adjuvant chemotherapy. Conclusion: This survey contributes to understanding of patients’ suffering of symptoms, their concerns and anxiety, and distress during their outpatient care. It also provides information on their thoughts and preferences for options of therapy. Altogether the study carries important implications for clinicians to plan more effective treatment and care for breast cancer patients.


Sign in / Sign up

Export Citation Format

Share Document